SGNPDL1V-001

Principal investigator

Dr. N. Steeghs

Medication

SGNPDL1V ADC with MMAE

Summary

This phase 1 study investigates the safety and tolerability of SGN-PDL1V in patients with advanced solid tumors. In addition, the maximum tolerated dose of SGN-PDL1V will be identified and a recommended dose and schedule will be established. The study will include multiple dose escalation tumor types (Part A), followed by dose and schedule optimization cohorts (Part B, optional) and disease-specific dose expansion cohorts (Part C).

Read more on heyleys.nl and clinicaltrials.gov

Patient population

Tumor type: NSCLC, Non Small Cell Lung Carcinoma, Lung Cancer / HNSCC, Squamous Cell Carcinoma of the Head and Neck Area / Esophagus Cancer, Esophagus Carcinoma / Breast Cancer, Breast Cancer
Tumor subtype: TNBC, triple negative breast carcinoma,
Tumor characteristics: PDL-1 positive

Notes

• Arm A escalation: HNSCC, NSCLC, THNBC, ESOPHAGEAL SCC – CLOSED
• Arm C: NSCLC (independent of PD-L1 expression) – closed
• Arm C: Monotherapy and Signal Seeking Cohort – closed
• Arm C: Biology cohort (NSCLC and HNSCC with negative PD-L1 expression, TNBC, esophageal SCC, melanoma, gastric cancer) – still closed
• Arm E: HNSCC (PDL1+) – open